Posted by Michael Wonder on 01 Aug 2018
Novelion Therapeutics announces marketing authorisation for Myalepta (metreleptin) in the European Union to treat generalised and partial lipodystrophy
31 July 2018 - Myalepta is the first approved therapy in Europe indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients.
Novelion Therapeutics today announced that the European Commission has granted marketing authorization for Myalepta (metreleptin), as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and above; or with confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.
